Vijay Pande, the former general partner who built Andreessen Horowitz's Bio + Health practice from the ground up, has launched a new venture firm that represents a dramatic departure from the scale of his previous role. As reported by TechCrunch, Pande's new firm, VZVC, co-founded with longtime investor Zach Werner, will make only a handful of concentrated investments annually, a stark contrast to the dozens of deals typical of a large venture portfolio.
"We're not doing 30 bets a year," Pande stated, outlining the firm's focused philosophy. The move follows Pande's unexpected departure in June 2025 from a16z, where he had managed close to $4 billion in assets.
Pande's shift from a mega-fund to a concentrated micro-fund marks a significant personal and professional pivot. His venture career began over a decade ago when a16z founders Marc Andreessen and Ben Horowitz, after initially avoiding the sector, recruited him to lead their foray into healthcare and life sciences. At the time, Pande was a Stanford chemistry professor renowned for creating Folding@home, the distributed-computing project that harnessed the power of millions of personal computers for biomedical research.
Over the following twelve years, Pande leveraged his deep scientific expertise to grow a16z's bio investment arm into one of the most formidable in Silicon Valley. His tenure saw the firm place major bets across biotechnology, health-tech, and computational biology, areas that have increasingly converged with artificial intelligence.
The operational model of VZVC is designed to be as lean as its investment thesis. The firm employs no associates and relies heavily on artificial intelligence for its day-to-day operations, a setup that allows the founding partners to maintain intense focus on a small number of portfolio companies. This approach suggests a belief that hands-on, capital-intensive support for a few chosen startups can outperform a spray-and-pray strategy, especially in complex, deep-tech fields like AI-driven biology.
This trend of high-profile investors leaving large, established firms to start focused, specialist funds has become increasingly common, but Pande's case is notable for the sheer scale he left behind. His move reflects a broader debate within venture capital about optimal fund size and partner bandwidth. As AI continues to lower the cost of diligence and operational overhead, it enables smaller teams to compete with larger institutions on insight and support, if not on checkbook size.
The founding of VZVC also signals continued confidence in the intersection of AI and life sciences, the very domain Pande helped pioneer at a16z. However, his new firm's strategy indicates a belief that the greatest returns in this computationally intensive field may not come from blanket coverage but from extremely selective, conviction-heavy betting. This philosophy may be particularly suited to a market environment that rewards capital efficiency and deep technical mentorship over sheer momentum investing.
While the specific targets of VZVC's first investments are not disclosed, the firm's structure and Pande's background point squarely at startups leveraging AI for drug discovery, clinical trial design, and personalized medicine. The firm's launch underscores the ongoing evolution of venture capital itself, where tools like AI are not just investment themes but foundational infrastructure that can reshape how capital is allocated and managed.
